As 2019 rolls in, we expect to see a flurry of approvals in the Japanese regenerative medicine arena, with regulatory decisions anticipated by the end of the year for Novartis Pharma’s CAR-T therapy and many more products, which could bring…
REGULATORY
MHLW Panel OKs 5-Year Extension of Pneumovax Transitional Measure
A health ministry panel agreed on January 10 to extend for five years a transitional measure related to the vaccination of MSD’s 23-valent pneumococcal vaccine Pneumovax in the elderly under the publicly funded immunization program. Pneumovax was added to the…
To read the full story
Related Article
- MHLW Panel to Discuss Changing Current Transitional Period for Pneumococcal Vaccinations in Elderly
November 2, 2018
- MHLW Presents Schedule for Discussions on Inclusion of 6 Vaccines in Public Vaccination Programs
May 21, 2018
- MHLW to Start Discussions on Pneumovax Vaccination in Post-Transition Period
September 15, 2017
REGULATORY
- Maviret, Ibrance, PD-1 Inhibitors under PMDA Risk Review
January 21, 2019
- MHLW to Give Enough Preparation Time for Local Govts before New PMD Law Takes Effect
January 21, 2019
- Iron Deficiency Med Ferinject Up for MHLW Panel Review on Jan. 31; No Vyvanse Discussion This Time
January 18, 2019
- MHLW Panels Find No Major Safety Concern for 14 Vaccines: July-October
January 17, 2019
- Nearly 1 Million People Newly Diagnosed with Cancer in Japan in 2016: MHLW
January 17, 2019
Takeda Pharmaceutical completed the £46 billion acquisition of Shire on January 8, vaulting itself into the top 10 league of…
To many people, Japan has always been one of the world’s most advanced economies and a market of rich opportunities with one of the top healthcare systems worldwide.Add a rapidly changing demographic, a declining workforce, and the constant challenges of…
While generic drugs post solid growth in volume-based shares in Japan, their makers are pondering ways to retool their business…